Divi’s Laboratories Limited has announced its audited financial results for the quarter and year ended March 31, 2026. For the quarter ended March 31, 2026, the company reported a standalone revenue from operations of ₹2793 crores, compared to ₹2578 crores in the previous quarter and ₹2536 crores in the corresponding quarter of the previous year. The standalone profit after tax for the current quarter stood at ₹756 crores, marking an increase from ₹598 crores in the previous quarter and ₹667 crores in the corresponding quarter of the previous year.
| Particulars | Q4 FY26 (₹ Cr) | Q3 FY26 (₹ Cr) | Q4 FY25 (₹ Cr) | QoQ Growth (%) | YoY Growth (%) |
|---|---|---|---|---|---|
| Revenue from Operations | 2793 | 2578 | 2536 | 8.34% | 10.13% |
| Profit for the Period | 756 | 598 | 667 | 26.42% | 13.34% |
Divi’s Laboratories Limited is a prominent Indian pharmaceutical company headquartered in Hyderabad, Telangana. The company specializes in the manufacture of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients for global markets.
Leave a Reply